Yu Zhu

Prof. Yu Zhu


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
LLLuo Lu
Luo Lu
YCYaoyu Chen
Yaoyu Chen
YZYu Zhu
Yu Zhu
The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer

7 March 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
YZYu Zhu
Yu Zhu
LLLuo Lu
Luo Lu
CQChun Qiao
Chun Qiao
YSYi Shan
Yi Shan
HLHuapeng Li
Huapeng Li
YCYaoyu Chen
Yaoyu Chen

2 September 2024 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
JLJing Lu
Jing Lu
HQHuiying Qiu
Huiying Qiu
YWYing Wang
Ying Wang
XZXin Zhou
Xin Zhou
HDHaiping Dai
Haiping Dai
SCSuning Chen
Suning Chen
Blinatumomab has emerged as a promising component of first-line therapy for acute B-cell precursor lymphoblastic leukemia (BCP-ALL), bolstering treatment efficacy. To mitigate CD19 selection pressure and reduce the incidence of blinatumomab-associated toxicities, pre-treatment chemotherapy is recommended before administering blinatumomab. From September 2022 to December 2023, we conducted a single-arm, multicenter, phase 2 trial (NCT05557110) in newly diagnosed Philadelphia chromosome-negative BCP-ALL (Ph-negative BCP-ALL) patients. Participants received induction treatment with reduced-dose chemotherapy (RDC), comprising idarubicin, vindesine, and dexamethasone over 7 days, followed by 2 weeks of blinatumomab. Those failing to achieve composite complete remission (CRc) received an additional 2 weeks of blinatumomab. The primary endpoint was the CRc rate post initial induction treatment. Of the 35 enrolled patients, 33 (94%) achieved CRc after 2 weeks of blinatumomab, with 30 (86%) achieving measurable residual disease (MRD) negativity. Two patients extended blinatumomab to 4 weeks. With either 2 or 4 weeks of blinatumomab treatment, all patients achieved CR (35/35) and 89% (31/35) were MRD negativity. The median time to CR was 22 days. Immune effector cell-associated neurotoxicity syndrome was limited (14%, all grade 1). Non-hematological adverse events of grade 3 or higher included pneumonia (17%), sepsis (6%), and cytokine release syndrome (9%). With a median follow-up of 11.5 months, estimated 1-year overall survival and 1-year progression-free survival rates were 97.1% and 82.2%, respectively. These findings affirm that RDC followed by blinatumomab is an effective and well-tolerated induction regimen for newly diagnosed Ph-negative BCP-ALL, supporting a shift towards less intensive and more targeted therapeutic approaches. Trial registration: https://www.clinicaltrials.Gov . Identifier NCT05557110.

29 March 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
XZXiaoli Zhao
Xiaoli Zhao
HYHua Yin
Hua Yin
NLNianyi Li
Nianyi Li
YZYu Zhu
Yu Zhu
WSWenyi Shen
Wenyi Shen
XWXiaoqin Wang
Xiaoqin Wang
Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders characterized by ineffective hematopoiesis, defective differentiation of hematopoietic precursors, and expansion of the abnormal clones. The prevalence of MDS has raised great concerns worldwide, but its pathogenetic mechanisms remain elusive. To provide insights on novel biomarkers for the diagnosis and therapy of MDS, we performed high-throughput genome-wide mRNA expression profiling, DNA methylation analysis, and long non-coding RNAs (lncRNA) analysis on bone marrows from four MDS patients and four age-matched healthy controls. We identified 1,937 differentially expressed genes (DEGs), 515 methylated genes, and 214 lncRNA that showed statistically significant differences. As the most significant module-related DEGs, TCL1A, PTGS2, and MME were revealed to be enriched in regulation of cell differentiation and cell death pathways. In addition, the GeneGo pathway maps identified by top DEGs were shown to converge on cancer, immunoregulation, apoptosis and regulation of actin cytoskeleton, most of which are known contributors in MDS etiology and pathogenesis. Notably, as potential biomarkers for diagnosis of MDS, four specific genes (ABAT, FADD, DAPP1, and SMPD3) were further subjected to detailed pathway analysis. Our integrative analysis on mRNA expression, gene methylation and lncRNAs profiling facilitates further understanding of the pathogenesis of MDS, and may promote the diagnosis and novel therapeutics for this disease.

20 January 2010 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
YZYu Zhu
Yu Zhu
JWJing Wang
Jing Wang
QHQian He
Qian He
JZJunqing Zhang
Junqing Zhang

8 May 2011 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
YZYu Zhu
Yu Zhu
QHQian He
Qian He
JWJing Wang
Jing Wang
HPHai-Feng Pan
Hai-Feng Pan